Home Cart Sign in  
Chemical Structure| 93265-81-7 Chemical Structure| 93265-81-7

Structure of Ropidoxuridine
CAS No.: 93265-81-7

Chemical Structure| 93265-81-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ropidoxuridine is a novel orally active halogenated thymidine analogue with potential radiotherapy sensitizing effects, suitable for sensitization treatment studies of various tumors.

Synonyms: IPdR

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ropidoxuridine

CAS No. :93265-81-7
Formula : C9H11IN2O4
M.W : 338.10
SMILES Code : O=C1N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=C(I)C=N1
Synonyms :
IPdR
MDL No. :MFCD13194773

Safety of Ropidoxuridine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312+H332-H315-H319-H361-H341
Precautionary Statements:P501-P261-P270-P202-P201-P271-P264-P280-P308+P313-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330-P302+P352+P312-P304+P340+P312-P405

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02381561 Advanced Bile Duct Carcinoma ... More >> Stage II Esophageal Cancer AJCC v7 Stage II Pancreatic Cancer AJCC v6 and v7 Stage IIA Esophageal Cancer AJCC v7 Stage IIA Pancreatic Cancer AJCC v6 and v7 Stage IIB Esophageal Cancer AJCC v7 Stage IIB Pancreatic Cancer AJCC v6 and v7 Stage III Colon Cancer AJCC v7 Stage III Esophageal Cancer AJCC v7 Stage III Gastric Cancer AJCC v7 Stage III Liver Cancer Stage III Pancreatic Cancer AJCC v6 and v7 Stage III Rectal Cancer AJCC v7 Stage III Small Intestinal Cancer AJCC v7 Stage IIIA Colon Cancer AJCC v7 Stage IIIA Esophageal Cancer AJCC v7 Stage IIIA Gastric Cancer AJCC v7 Stage IIIA Rectal Cancer AJCC v7 Stage IIIA Small Intestinal Cancer AJCC v7 Stage IIIB Colon Cancer AJCC v7 Stage IIIB Esophageal Cancer AJCC v7 Stage IIIB Gastric Cancer AJCC v7 Stage IIIB Rectal Cancer AJCC v7 Stage IIIB Small Intestinal Cancer AJCC v7 Stage IIIC Colon Cancer AJCC v7 Stage IIIC Esophageal Cancer AJCC v7 Stage IIIC Gastric Cancer AJCC v7 Stage IIIC Rectal Cancer AJCC v7 Stage IV Colon Cancer AJCC v7 Stage IV Esophageal Cancer AJCC v7 Stage IV Gastric Cancer AJCC v7 Stage IV Liver Cancer Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IV Rectal Cancer AJCC v7 Stage IV Small Intestinal Cancer AJCC v7 Stage IVA Colon Cancer AJCC v7 Stage IVA Liver Cancer Stage IVA Rectal Cancer AJCC v7 Stage IVB Colon Cancer AJCC v7 Stage IVB Liver Cancer Stage IVB Rectal Cancer AJCC v7 Less << Phase 1 Recruiting - United States, Rhode Island ... More >> Rhode Island Hospital Recruiting Providence, Rhode Island, United States, 02903 Contact: Timothy J. Kinsella    401-444-8311    tkinsella@lifespan.org    Principal Investigator: Timothy J. Kinsella Less <<
NCT02993146 Metastatic Malignant Neoplasm ... More >> Metastatic Malignant Neoplasm in the Brain Less << Phase 1 Recruiting August 1, 2019 United States, California ... More >> UC San Diego Moores Cancer Center Active, not recruiting La Jolla, California, United States, 92093 University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact    916-734-3089       Principal Investigator: Karen L. Kelly          United States, Iowa University of Iowa/Holden Comprehensive Cancer Center Recruiting Iowa City, Iowa, United States, 52242 Contact: Site Public Contact    800-237-1225       Principal Investigator: Mohammed M. Milhem          United States, Maryland University of Maryland/Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Site Public Contact    800-888-8823       Principal Investigator: Pranshu Mohindra          United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Site Public Contact    800-865-1125       Principal Investigator: Michelle M. Kim          United States, New York Columbia University/Herbert Irving Cancer Center Active, not recruiting New York, New York, United States, 10032 United States, Pennsylvania Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Site Public Contact    215-728-4790       Principal Investigator: Stephanie E. Weiss          United States, Texas Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact    713-798-1354    burton@bcm.edu    Principal Investigator: Jacob Mandel          Ben Taub General Hospital Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact    713-873-2000       Principal Investigator: Jacob Mandel          United States, Utah Huntsman Cancer Institute/University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu    Principal Investigator: Lindsay M. Burt Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.79mL

2.96mL

1.48mL

29.58mL

5.92mL

2.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records